Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.151S017
European Journal of Endocrinology, Vol 151, Suppl_1, S17-S22
Copyright © 2004 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jenkins, P.
Right arrow Articles by Bustin, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jenkins, P.
Right arrow Articles by Bustin, S.
Articles

Evidence for a link between IGF-I and cancer

PJ Jenkins and SA Bustin

Department of Endocrinology, St Bartholomew's Hospital, London EC1A 7BE, UK. P.J.Jenkins@qmul.ac.uk

Cancer risk is determined by a combination of environmental factors and genetic predisposition. Recent evidence suggests that dietary and related factors such as physical activity and body size may influence cancer risk through their effects on the serum concentration of IGF-I and its binding proteins. The growth hormone (GH)/IGF-I axis is involved in both human development as well as the maintenance of normal function and homeostasis in most cells of the body. In addition to their classical role as endocrine hormones, its members regulate a wide range of biological functions such as cell proliferation, differentiation and apoptosis through paracrine and autocrine mechanisms. During cancer development this complex network regulating tissue homeostasis breaks down, with inappropriate expression of the GH/IGF-I axis making an important contribution. The increased understanding of the molecular mechanisms and signalling pathways regulated by the GH/IGF-I axis has started to provide significant insights into the aetiology, prevention and therapy for a number of common cancers.


This article has been cited by other articles:


Home page
 FASEB J.Home page
K. A. Varady, D. J. Roohk, B. K. McEvoy-Hein, B. D. Gaylinn, M. O. Thorner, and M. K. Hellerstein
Modified alternate-day fasting regimens reduce cell proliferation rates to a similar extent as daily calorie restriction in mice
FASEB J, June 1, 2008; 22(6): 2090 - 2096.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
K. A. Varady, D. J. Roohk, and M. K. Hellerstein
Dose effects of modified alternate-day fasting regimens on in vivo cell proliferation and plasma insulin-like growth factor-1 in mice
J Appl Physiol, August 1, 2007; 103(2): 547 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Sato, T. Yazawa, T. Suzuki, H. Shimoyamada, K. Okudela, M. Ikeda, K. Hamada, H. Yamada-Okabe, M. Yao, Y. Kubota, et al.
Growth Regulation via Insulin-Like Growth Factor Binding Protein-4 and -2 in Association with Mutant K-ras in Lung Epithelia
Am. J. Pathol., November 1, 2006; 169(5): 1550 - 1566.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. M. Adhami, F. Afaq, and H. Mukhtar
Insulin-like growth factor-I axis as a pathway for cancer chemoprevention.
Clin. Cancer Res., October 1, 2006; 12(19): 5611 - 5614.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Bjorndahl, R. Cao, L. J. Nissen, S. Clasper, L. A. Johnson, Y. Xue, Z. Zhou, D. Jackson, A. Jon Hansen, and Y. Cao
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo
PNAS, October 25, 2005; 102(43): 15593 - 15598.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 European Society of Endocrinology.